Results 121 to 130 of about 2,548 (156)

Melanoma-specific mutation hotspots in distal, non-coding, promoter-interacting regions implicate novel candidate driver genes. [PDF]

Br J Cancer
Pudjihartono M, Pudjihartono N, O'Sullivan JM, Schierding W.   +3 more
europepmc   +1 more source

Integrated bioinformatics investigation of adenylyl cyclase family co-expression network in bladder cancer followed by preliminary validation of member 2 (ADCY2) in tumorigenesis and prognosis. [PDF]

Transl Cancer Res
Wang H, Luo W, Ji J, Qu M, Jiang S, Zhang J, Zhou Z, Chen W, Nian X, Zhang W, Wang Y.   +10 more
europepmc   +1 more source

Impact of pesticide diazinon on gastric cancer cell lines and the alteration of cholinergic and serotonergic pathway genes affecting cell proliferation. [PDF]

Sci Rep
Ghaemi S, Abedini F, Mousavi A, Ahangari G.   +3 more
europepmc   +1 more source

Single-Cell RNA-Seq Uncovers Robust Glial Cell Transcriptional Changes in Methamphetamine-Administered Mice. [PDF]

Int J Mol Sci
Oladapo A, Deshetty UM, Callen S, Buch S, Periyasamy P.   +4 more
europepmc   +1 more source

Dynamic Transcriptional Regulation of the Hypothalamic-Pituitary-Testis Axis in the Seasonally Breeding Teleost <i>Sebastes schlegelii</i>. [PDF]

Int J Mol Sci
Wang X, Liu Q, Li J.
europepmc   +1 more source

The ADCY9 genetic variants are associated with glioma susceptibility and patient prognosis

Genomics, 2020
Genetic factor is a risk factor in glioma occurrence. This study was designed to detect the effect of ADCY9 polymorphisms on glioma risk and prognosis.We performed a case-control study of 1080 participants (584 cases and 496 controls) to assess the relationship of ADCY9 polymorphisms with the risk and prognosis of glioma among the Chinses Han ...
Gang Zhang, Min Xi, Yuqian Li, Liang Wang, Li Gao, Luyi Zhang, Zhangkai Yang, Hangyu Shi   +7 more
openalex   +3 more sources

Abstract 624: Interactions Between Adenylate Cyclase Type 9 (ADCY9) and Cholesteryl Ester Transfer Protein (CETP) in Atherosclerosis [PDF]

Arteriosclerosis, Thrombosis, and Vascular Biology, 2018
AbstractBackgroundCETP inhibitors raise circulating concentrations of HDL-cholesterol, and potent inhibitors also lower non-HDL-cholesterol and risk of vascular disease. Previous genome-wide pharmacogenetic analysis of a phase III randomized controlled trial (RCT) of the CETP inhibitor, dalcetrapib, found variants in ADCY9 to associate with response to
Yohann Rautureau, Vanessa Deschambault, Marie‐Eve Higgins, Daniel Rivas, Mélanie Mecteau, Pierre A. Geoffroy, Géraldine Miquel, Kurunradeth Uy, Rocío Sánchez, Audrey Nault, Pierre-Marc Williams, María Laura Suárez, Geneviève Brand, Line Lapointe, Natacha Duquette, Marc‐Antoine Gillis, Samaneh Samami, Gaétan Mayer, Philippe Pouliot, Adeline Raignault, Foued Maafi, Mathieu R. Brodeur, Sylvie Lévesque, Marie‐Claude Guertin, Marie‐Pierre Dubé, Éric Thorin, David Rhainds, Éric Rhéaume, Jean‐Claude Tardif   +28 more
  +4 more sources